Role of MYC in Medulloblastoma
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2013)
期刊
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
卷 3, 期 11, 页码 -出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
关键词
资金
- National Institutes of Health [CA-096832, CA-21765]
- American Lebanese-Syrian Associated Charities (AL-SAC) of St. Jude Children's Research Hospital (SJCRH)
作者
我是这篇论文的作者
推荐
Targeting protein folding in N-Myc-driven medulloblastoma
Gintvile Valinciute, Martine F. Roussel
MOLECULAR ONCOLOGY (2023)
EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression
Arthur R. Wolin, Melanie Y. Vincent, Taylor Hotz, Stephen C. Purdy, Sheera R. Rosenbaum, Connor J. Hughes, Jessica Y. Hsu, Michael U. J. Oliphant, Brock Armstrong, Veronica Wessells, Marileila Varella-Garcia, Matthew D. Galbraith, Angela Pierce, Dong Wang, Sujatha Venkataraman, Etienne Danis, Bethany Veo, Natalie Serkova, Joaquin M. Espinosa, Daniel L. Gustafson, Rajeev Vibhakar, Heide L. Ford
NEURO-ONCOLOGY (2023)
A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma
Dong Wang, Angela Pierce, Bethany Veo, Susan Fosmire, Etienne Danis, Andrew Donson, Sujatha Venkataraman, Rajeev Vibhakar
CANCERS (2021)
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma
Jonas Ecker, Venu Thatikonda, Gianluca Sigismondo, Florian Selt, Gintvile Valinciute, Ina Oehme, Carina Mueller, Juliane L. Buhl, Johannes Ridinger, Diren Usta, Nan Qin, Cornelis M. van Tilburg, Christel Herold-Mende, Marc Remke, Felix Sahm, Frank Westermann, Marcel Kool, Robert J. Wechsler-Reya, Lukas Chavez, Jeroen Krijgsveld, Natalie Jaeger, Stefan M. Pfister, Olaf Witt, Till Milde
NEURO-ONCOLOGY (2021)
N-myc-Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
Duygu Kuzuoglu-Ozturk, Ozlem Aksoy, Christin Schmidt, Robin Lea, Jon D. Larson, Ryan R. L. Phelps, Nicole Nasholm, Megan Holt, Adrian Contreras, Miller Huang, Shannon Wong-Michalak, Hao Shao, Robert Wechsler-Reya, Joanna J. Phillips, Jason E. Gestwicki, Davide Ruggero, William A. Weiss
CANCER RESEARCH (2023)
Noncanonical activation of GLI signaling in SOX2+ cells drives medulloblastoma relapse
Marzena Swiderska-Syn, Julia Mir-Pedrol, Alexander Oles, Olga Schleuger, April D. Salvador, Sean M. Greiner, Cara Seward, Fan Yang, Benjamin R. Babcock, Chen Shen, Daniel T. Wynn, Avencia Sanchez-Mejias, Timothy R. Gershon, Vanesa Martin, Heather J. McCrea, Kathryn G. Lindsey, Carsten Krieg, Jezabel Rodriguez-Blanco
SCIENCE ADVANCES (2022)
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy
Dong Wang, Bethany Veo, Angela Pierce, Susan Fosmire, Krishna Madhavan, Ilango Balakrishnan, Andrew Donson, Irina Alimova, Kelly D. Sullivan, Molishree Joshi, Mark Erlander, Maya Ridinger, Nicholas K. Foreman, Sujatha Venkataraman, Rajeev Vibhakar
NEURO-ONCOLOGY (2022)
MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice
Carolin Goebel, Shweta Godbole, Melanie Schoof, Doerthe Holdhof, Catena Kresbach, Carolin Loose, Julia Neumann, Ulrich Schueller
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2023)
Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma
Raelene Endersby, Jacqueline Whitehouse, Allison Pribnow, Mani Kuchibhotla, Hilary Hii, Brooke Carline, Suresh Gande, Jennifer Stripay, Mathew Ancliffe, Meegan Howlett, Tobias Schoep, Courtney George, Clara Andradas, Patrick Dyer, Marjolein Schluck, Brett Patterson, Silvia K. Tacheva-Gigorova, Matthew N. Cooper, Giles Robinson, Clinton Stewart, Stefan M. Pfister, Marcel Kool, Till Milde, Amar Gajjar, Terrance Johns, Robert J. Wechsler-Reya, Martine F. Roussel, Nicholas G. Gottardo
SCIENCE TRANSLATIONAL MEDICINE (2021)
Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma
Emma Martell, Helgi Kuzmychova, Esha Kaul, Harshal Senthil, Subir Roy Chowdhury, Ludivine Coudiere Morrison, Agnes Fresnoza, Jamie Zagozewski, Chitra Venugopal, Chris M. Anderson, Sheila K. Singh, Versha Banerji, Tamra E. Werbowetski-Ogilvie, Tanveer Sharif
NATURE COMMUNICATIONS (2023)
Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma
Virender Kumar, Qiyue Wang, Bharti Sethi, Feng Lin, Vinod Kumar, Donald W. Coulter, Yuxiang Dong, Ram Mahato
BIOMATERIALS (2021)
STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo
Kyle A. Rohrer, Heyu Song, Anum Akbar, Yingling Chen, Suravi Pramanik, Phillip J. Wilder, Erin M. McIntyre, Nagendra K. Chaturvedi, Kishor K. Bhakat, Angie Rizzino, Don W. Coulter, Sutapa Ray
CANCERS (2023)
Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability
Zaili Luo, Dazhuan Xin, Yunfei Liao, Kalen Berry, Sean Ogurek, Feng Zhang, Liguo Zhang, Chuntao Zhao, Rohit Rao, Xinran Dong, Hao Li, Jianzhong Yu, Yifeng Lin, Guoying Huang, Lingli Xu, Mei Xin, Ryuichi Nishinakamura, Jiyang Yu, Marcel Kool, Stefan M. Pfister, Martine F. Roussel, Wenhao Zhou, William A. Weiss, Paul Andreassen, Q. Richard Lu
NATURE COMMUNICATIONS (2023)
Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts
Kristin L. Leskoske, Krystine Garcia-Mansfield, Ritin Sharma, Aparna Krishnan, Jessica M. Rusert, Jill P. Mesirov, Robert J. Wechsler-Reya, Patrick Pirrotte
JOURNAL OF PROTEOME RESEARCH (2022)
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Matthew J. Kling, Varun Kesherwani, Nitish K. Mishra, Gracey Alexander, Erin M. McIntyre, Sutapa Ray, Kishore B. Challagundla, Shantaram S. Joshi, Don W. Coulter, Nagendra K. Chaturvedi
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility
Anthony Pak-Yin Liu, Paul A. Northcott, Giles W. Robinson, Amar Gajjar
LABORATORY INVESTIGATION (2022)
Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study
John T. Lucas, Christopher L. Tinkle, Jie Huang, Arzu Onar-Thomas, Sudharsan Srinivasan, Parker Tumlin, Jared B. Becksfort, Paul Klimo, Frederick A. Boop, Giles W. Robinson, Brent A. Orr, Julie H. Harreld, Matthew J. Krasin, Paul A. Northcott, David W. Ellison, Amar Gajjar, Thomas E. Merchant
NEURO-ONCOLOGY (2022)
The posterior fossa syndrome questionnaire: using science to inform practice
Molly E. Wickenhauser, Raja B. Khan, Darcy Raches, Jason M. Ashford, Kathryn M. W. Russell, Kristin Lyons, Giles W. Robinson, Amar Gajjar, Paul Klimo, Heather M. Conklin
JOURNAL OF NEURO-ONCOLOGY (2022)
Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor
Santhosh A. Upadhyaya, Olivia Campagne, Catherine A. Billups, Brent A. Orr, Arzu Onar-Thomas, Ruth G. Tatevossian, Roya Mostafavi, Jason R. Myers, Anna Vinitsky, Daniel C. Moreira, Holly B. Lindsay, Lindsay Kilburn, Patricia Baxter, Amy Smith, John R. Crawford, Sonia Partap, Anne E. Bendel, Dolly G. Aguilera, Kim E. Nichols, Evadnie Rampersaud, David W. Ellison, Paul Klimo, Zoltan Patay, Giles W. Robinson, Alberto Broniscer, Clinton F. Stewart, Cynthia Wetmore, Amar Gajjar
NEURO-ONCOLOGY (2023)
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
Ami Desai, Giles W. Robinson, Karen Gauvain, Ellen M. Basu, Margaret E. Macy, Luke Maese, Nicholas S. Whipple, Amit J. Sabnis, Jennifer H. Foster, Suzanne Shusterman, Janet Yoon, Brian D. Weiss, Mohamed S. Abdelbaki, Amy E. Armstrong, Thomas Cash, Christine A. Pratilas, Nadege Corradini, Lynley Marshall, Mufiza Farid-Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses-Lorente, Alison Cardenas, Katherine E. Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox
NEURO-ONCOLOGY (2022)
Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
Allison Pribnow, Barbara Jonchere, Jingjing Liu, Kyle S. Smith, Olivia Campagne, Ke Xu, Sarah Robinson, Yogesh Patel, Arzu Onar-Thomas, Gang Wu, Clinton F. Stewart, Paul A. Northcott, Jiyang Yu, Giles W. Robinson, Martine F. Roussel
MOLECULAR CANCER THERAPEUTICS (2022)
Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome
Samuel S. McAfee, Silu Zhang, Ping Zou, Heather M. Conklin, Darcy Raches, Giles Robinson, Amar Gajjar, Raja Khan, Paul Klimo, Zoltan Patay, Matthew A. Scoggins
NEURO-ONCOLOGY (2023)
Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
Barbara Jonchere, Justin Williams, Frederique Zindy, Jingjing Liu, Sarah Robinson, Dana M. Farmer, Jaeki Min, Lei Yang, Jennifer L. Stripay, Yingzhe Wang, Burgess B. Freeman, Jiyang Yu, Anang A. Shelat, Zoran Rankovic, Martine F. Roussel
MOLECULAR CANCER THERAPEUTICS (2023)
From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors
Mladen Koravovic, Anand Mayasundari, Gordana Tasic, Fatemeh Keramatnia, Timothy R. Stachowski, Huarui Cui, Sergio C. Chai, Barbara Jonchere, Lei Yang, Yong Li, Xiang Fu, Ryan Hiltenbrand, Leena Paul, Vibhor Mishra, Jeffery M. Klco, Martine F. Roussel, William CK. Pomerantz, Marcus Fischer, Zoran Rankovic, Vladimir Savic
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)
Targeting protein folding in N-Myc-driven medulloblastoma
Gintvile Valinciute, Martine F. Roussel
MOLECULAR ONCOLOGY (2023)
ENTRECTINIB IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH EXTRACRANIAL SOLID OR PRIMARY CNS TUMOURS HARBOURING NTRK1/2/3, ROS1, OR ALK FUSIONS: UPDATED DATA FROM STARTRK-NG
Ami Desai, Giles Robinson, Ellen Basu, Jennifer Foster, Amit Sabnis, Luke Maese, Janet Yoon, Thomas Cash, Christine Pratilas, Yeming Wu, Daniel Morgenstern, Cornelis Van Tilburg, Michela Casanova, Quentin Campbell-Hewson, Arnauld Verschuur, Lynley Marshall, Dennis T. L. Ku, Nadege Corradini, Huanmin Wang, Saibah Chohan, Alison Cardenas, Katherine Hutchinson, Clare Devlin, Jade Wulff, Amar Gajjar, Elisabeth Fox
PEDIATRIC BLOOD & CANCER (2022)
RELAPSE SHH MEDULLOBLASTOMA (MB) IN YOUNG CHILDREN. ARE THERE ALTERNATIVES TO FULL-DOSE CRANIOSPINAL IRRADIATION?
Craig Erker, Brandon Craig, Simon Bailey, Maura Massimino, Valerie Larouche, Jonathan Finlay, Cassie Kline, George Michaiel, Ashley Margol, Kenneth Cohen, Chantel Cacciotti, Virginia Harrods, Kathleen Dorris, Mohammed Abdelbaki, Nisreen Amayiri, Zhihong Wang, Jordan Hansford, Juliette Hukin, Ralph Salloum, Lindsay Hoffmann, Jeffrey Murray, Kevin Ginn, Michal Zapotocky, Lorena Baroni, Stephen Gilheens, Dolly Aguiera, Claire Mazewski, Shafqat Shah, Douglas Strother, Amar Gajjar, Sabine Mueller, Paul Northcott, Steve Clifford, Giles Robinson, Eric Bouffet, Lucie Lafay-Cousin
PEDIATRIC BLOOD & CANCER (2022)
SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES
Paul Northcott, Kyle Smith, Rahul Kumar, Leena Paul, Laure Bihannic, Tong Lin, Kendra Maass, Kristian Pajtler, Murali Chintagumpala, Jack Su, Eric Bouffet, Michael Fisher, Sridharan Gururangan, Richard Cohn, Tim Hassall, Jordan Hansford, Paul Klimo, Frederick Boop, Clinton Stewart, Julie Harreld, Thomas Merchant, Ruth Tatevossian, Geoffrey Neale, Matthew Lear, Jeffery Klco, Brent Orr, David Ellison, Richard Gilbertson, Arzu Onar-Thomas, Amar Gajjar, Giles Robinson
NEURO-ONCOLOGY (2022)
CLINICAL AND MOLECULAR META-ANALYSIS OF THREE MAJOR MEDULLOBLASTOMA CLINICAL TRIALS (ACNS0331, SJMB03, ACNS0332) UNCOVERS NOVEL STRATEGIES TO IMPROVE RISK-STRATIFIED THERAPY
Kyle S. Smith, Catherine A. Billups, Sandeep K. Dhanda, Laure Bihannic, Aksana Vasilyeva, Yimei Li, Jeff M. Michalski, James M. Olsen, Sarah Leary, Maryam Fouladi, Amar Gajjar, Arzu Onar, Paul A. Northcott, Giles W. Robinson
NEURO-ONCOLOGY (2022)
SJ901: PHASE I/II EVALUATION OF SINGLE AGENT MIRDAMETINIB (PD-0325901), A BRAIN-PENETRANT MEK1/2 INHIBITOR, FOR THE TREATMENT OF CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH LOW-GRADE GLIOMA (LGG)
Anna Vinitsky, Jason Chiang, Asim K. Bag, Olivia Campagne, Clinton F. Stewart, Paige Dunphy, Barry Shulkin, Qian Li, Tong Lin, Mary Ellen Hoehn, Jason N. Johnson, Jeffrey A. Towbin, Raja Khan, Ruth G. Tatevossian, Gregory T. Armstrong, Brian Potter, Heather Conklin, Todd Shearer, Susan Scott, Giles W. Robinson
NEURO-ONCOLOGY (2022)